Animal model of Relapsing-Remitting Multiple Sclerosis

Newsletter # 38

Animal models

Multiple sclerosis (MS), an inflammatory, autoimmune and demyelinating disease of the central nervous system, affects about 2.5 million people worldwide.
Relapsing-remitting MS (RRMS) is the most common disease course at the time of diagnosis.
Approximately 85-90% of individuals with MS are initially diagnosed with RRMS.

MS is studied in the animal model of experimental autoimmune encephalomyelitis (EAE). However, very limited data are available in the literature about EAE model that closely mimics the clinical symptoms of RRMS.

NEUROFIT offers a validated animal model testing (rat) for Multiple Sclerosis (MS) with period of remission and relapse, as seen in human MS.

  • Validated animal model testing for MS with period of remission and relapse, as seen in human MS.

    Time course of clinical disability in rats treated with placebo versus rat treated with Fingolimod. Oral treatment with Fingolimod is initiated at remission from the attack
    (day 16).

  • In this experimental model, the disease relapse is prevented by oral FTY720 (Fingolimod : Gilenya®), a clinically approved drug for MS.

    Comparison of disease severity in placebo and Fingolimod-treated rats.

    This model also responds to DEXAMATHASONE, another clinically effective drug for the treatment of acute relapse.

NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us. Privacy Policy
On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please sign up on our mailing list: